Here’s the first RESTART newsletter!

The British Heart Foundation has funded this trial for five years, starting 1 March 2013.

RESTART aims to establish whether adults surviving spontaneous (non-traumatic) intracerebral haemorrhage (ICH), who had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease before the ICH, experience a beneficial reduction of all serious vascular events over at least two years from a policy of starting antiplatelet drugs compared to a policy of avoiding antiplatelet drugs.

We are finalising the trial database and documentation in preparation for start-up at two sites in Edinburgh in May to pilot our systems. After this has been done we will initiate other sites.

Thank you to the 125 sites that have expressed interest. We are delighted that 72 sites have also provided complete registration forms. With the information provided, we will make the submission of the SSI as easy for each site as possible.

We will be in touch with each of these 72 sites to let them know when we can begin the site initiation process. This will include collection of all of the necessary regulatory documents and test brain images, completion of the online training modules and a site initiation teleconference. We will start the site initiation process first at sites able to provide brain imaging in the MRI sub-study.

Meantime, please come and join us at our stand or collaborators meeting at the European Stroke Conference in London in May.